✦ LIBER ✦

A DOUBLE-BLIND TRIAL WITH BACLOFEN (LIORESAL®) AND DIAZEPAM IN SPASTICITY DUE TO MULTIPLE SCLEROSIS

✍ Scribed by Arne From; Anne Heltberg

Book ID: 114780424
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 412 KB
Volume: 51
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1975.tb01366.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The treatment of spasticity in multiple

The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen

✍ R. Stien; H.J. Nordal; S.I. Oftedal; M. Sletteboø 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB

Computer-aided retraining of memory and

Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial

✍ Alessandra Solari; Achille Motta; Laura Mendozzi; Eugenio Pucci; Marco Forni; Gi 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 221 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

A randomised, double blind, placebo cont

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon -1b in patients with multiple sclerosis

✍ Soilu-Hanninen, M.; Aivo, J.; Lindstrom, B.-M.; Elovaara, I.; Sumelahti, M.-L.; 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 153 KB

Safety and efficacy of fingolimod in pat

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

✍ Calabresi, Peter A; Radue, Ernst-Wilhelm; Goodin, Douglas; Jeffery, Douglas; Ram 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 290 KB

A randomised, double blind, placebo cont

A randomised, double blind, placebo controlled trial with vitamin D 3 as an add on treatment to interferon β-1b in patients with multiple sclerosis

✍ Soilu-Hänninen, Merja (author);Åivo, Julia (author);Lindström, Britt Marie (auth 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 153 KB